Molecular evidence of cryptotanshinone for treatment and prevention of human cancer
about
HS-133, a novel fluorescent phosphatidylinositol 3-kinase inhibitor as a potential imaging and anticancer agent for targeted therapyCryptotanshinone induces cell cycle arrest and apoptosis through the JAK2/STAT3 and PI3K/Akt/NFκB pathways in cholangiocarcinoma cells.Salvia miltiorrhiza extract dihydrotanshinone induces apoptosis and inhibits proliferation of glioma cells.Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).Combined metabolome and transcriptome profiling provides new insights into diterpene biosynthesis in S. pomifera glandular trichomesA promising "TRAIL" of tanshinones for cancer therapy.Cryptotanshinone inhibits oxidized LDL-induced adhesion molecule expression via ROS dependent NF-κB pathways.Dihydrotanshinone I Attenuates Atherosclerosis in ApoE-Deficient Mice: Role of NOX4/NF-κB Mediated Lectin-Like Oxidized LDL Receptor-1 (LOX-1) of the Endothelium.Cryptotanshinone inhibition of mammalian target of rapamycin pathway is dependent on oestrogen receptor alpha in breast cancer.Apoptosis Induced by Tanshinone IIA and Cryptotanshinone Is Mediated by Distinct JAK/STAT3/5 and SHP1/2 Signaling in Chronic Myeloid Leukemia K562 Cells.Inhibition of PI3K/Akt/mTOR signaling by natural products.Antitumor and radiosensitizing synergistic effects of apigenin and cryptotanshinone against solid Ehrlich carcinoma in female mice.Cryptotanshinone exhibits therapeutical effects on cerebral stroke through the PI3K/AKT‑eNOS signaling pathway.Inhibitory effects of isocryptotanshinone on gastric cancer.Cryptotanshinone Induces Cell Cycle Arrest and Apoptosis of NSCLC Cells through the PI3K/Akt/GSK-3β Pathway
P2860
Q28383826-9DA67C1A-10A3-40B3-BC31-837BC180A183Q32174351-53A7865E-0105-43DB-8C49-CFF771CA53A4Q32177594-4BDA364E-9692-40E2-A86F-101BD7FE90C5Q34155125-AD7B917E-5D36-4A63-B7F2-09F45DC0682AQ35842628-54F38403-719B-46CC-95B3-2F5D0D471A96Q36332681-1CC86594-8F12-4A24-832E-4B01B171B2E5Q37109342-6FBF042B-120F-4F9C-B2A3-14CBDF91CB71Q37408943-4B50EB7E-AA0F-49F8-B0AA-8539CC00F76CQ41520280-5C9794AF-C995-4874-A26C-43B5D40EE9EEQ42044041-50EF3DE6-2225-4826-977C-596ADB7E4874Q42108388-E6457E6C-1CF9-4699-823C-FB417B1CE8CBQ46851514-082D623A-5A14-410F-B70E-37ABDEB842E8Q47388142-A219A2D1-E39E-4012-A5ED-CAC56A9B6658Q55343616-DA372D04-6C3E-40B4-8287-9354F0008CEAQ58742499-AAC8651D-EDD6-488D-AB54-551BA0BAD5EC
P2860
Molecular evidence of cryptotanshinone for treatment and prevention of human cancer
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Molecular evidence of cryptotanshinone for treatment and prevention of human cancer
@ast
Molecular evidence of cryptotanshinone for treatment and prevention of human cancer
@en
type
label
Molecular evidence of cryptotanshinone for treatment and prevention of human cancer
@ast
Molecular evidence of cryptotanshinone for treatment and prevention of human cancer
@en
prefLabel
Molecular evidence of cryptotanshinone for treatment and prevention of human cancer
@ast
Molecular evidence of cryptotanshinone for treatment and prevention of human cancer
@en
P2093
P2860
P1476
Molecular evidence of cryptotanshinone for treatment and prevention of human cancer
@en
P2093
Guangying Chen
Wenxing Chen
P2860
P304
P356
10.2174/18715206113139990115
P50
P577
2013-09-01T00:00:00Z